- Services
Abuse Liability & Abuse Deterrence Support
Altreos provides scientific and regulatory support for abuse liability assessment and abuse-deterrent strategies across the development lifecycle of CNS-active products and nicotine or tobacco products. The focus is on aligning study design, evidence generation, and regulatory positioning so that data packages withstand detailed review.
Key areas of support:
- Overall abuse liability and abuse-deterrent strategy for new and reformulated CNS products
- Design and interpretation of human abuse potential (HAP) studies across routes of administration
- Integration of nonclinical, clinical, and post-marketing data into a coherent abuse risk narrative
- Evaluation of tampering, misuse, diversion, dependence, and withdrawal data
- Abuse-deterrent formulation strategy, including route-specific claims and study expectations
- Preparation of 8-factor analyses and other documents supporting scheduling and labeling decisions
- Input on risk management and labeling language related to abuse, misuse, and addiction
- Services
Frequently Asked Questions
What types of products does this service cover?
Covers CNS-active drugs and nicotine or tobacco products, including NMEs, reformulations, and abuse-deterrent formulations of opioids, stimulants, sedatives, cannabinoids, hallucinogens, dissociatives, and related classes.
At what stage of development is abuse liability input most valuable?
Value is highest when engaged before key study designs are finalized, typically during late nonclinical or early clinical phases, so that the abuse liability strategy and HAP program are built into the development plan rather than added reactively.
How is a human abuse potential study designed?
Design considers mechanism of action, expected effects, comparators, routes of administration, dose selection, subject population, and endpoints (subjective, behavioral, and pharmacokinetic), all in the context of current regulatory expectations.
What is the difference between abuse liability assessment and abuse-deterrent evaluation?
Abuse liability assessment characterizes the intrinsic potential for abuse, misuse, dependence, and withdrawal. Abuse-deterrent evaluation assesses whether a formulation meaningfully reduces the likelihood or extent of abuse via specific routes, relative to appropriate comparators.
Can Altreos assist if studies have already been completed?
Yes. Support can include critical review of completed studies, reinterpretation of results in light of regulatory feedback, development of integrated abuse narratives, and identification of any remaining data gaps before submission.
Does this service include drafting regulatory documents?
Yes. Typical outputs include 8-factor analyses, sections of IND/NDA dossiers, briefing packages for agency meetings, and written responses to abuse-related regulatory questions.